Vinod Shetty, MD
Internal Medicine · Howell, NJNPI 1366580581
Payments from drug & device makers
Across 350 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$610
- AstraZeneca$478
- Lilly USA, LLC$409
- Pfizer$286
- Exact Sciences$280
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,280100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $1,062 |
| GSK | 41 | $610 |
| AstraZeneca | 33 | $478 |
| Lilly USA, LLC | 26 | $409 |
| Pfizer | 16 | $286 |
| Exact Sciences | 10 | $280 |
| Abbott | 14 | $248 |
| Novo Nordisk | 14 | $235 |
| Sanofi-aventis U.S. LLC | 14 | $213 |
| Merck | 12 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $135 |
| Johnson & Johnson | 8 | $125 |
| Bayer | 4 | $95 |
| Novartis | 6 | $94 |
| Sanofi Pasteur Inc. | 6 | $93 |
| Astellas Pharma US Inc | 6 | $83 |
| Avanir Pharmaceuticals, Inc. | 5 | $64 |
| Amarin Pharma, Inc. | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $44 |
| Genentech USA, Inc. | 3 | $43 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Aytu Biopharma, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Amgen | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $13 |
How this compares
$5,286 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $80,703 |
| OzempicSemaglutide | 44 | $53,827 |
| XareltoRivaroxaban | 45 | $45,609 |
| JardianceEmpagliflozin | 31 | $43,789 |
| FarxigaDapagliflozin Propanediol | 22 | $24,516 |
| MounjaroTirzepatide | 18 | $22,866 |
| TrulicityDulaglutide | 12 | $21,264 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $20,852 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $19,043 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $15,638 |
| MyrbetriqMirabegron | 20 | $15,310 |
| JanuviaSitagliptin Phosphate | 11 | $12,230 |
| Levothyroxine Sodium | 468 | $5,654 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $5,064 |
| Rosuvastatin Calcium | 301 | $5,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $286 | $80,70372 claims |
| Novo NordiskOzempic | $235 | $53,82744 claims |
| Johnson & JohnsonXarelto | $125 | $45,60945 claims |
| Lilly USA, LLCMounjaro, Trulicity | $409 | $44,12930 claims |
| Boehringer IngelheimJardiance | $15 | $43,78931 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $610 | $36,49056 claims |
| MerckJanumet Xr, Januvia | $171 | $31,27229 claims |
| AstraZenecaFarxiga, Symbicort | $478 | $27,78536 claims |
| Astellas Pharma US IncMyrbetriq | $83 | $15,31020 claims |
| AbbVieSynthroid | $1,062 | $4,506104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Howell
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.